The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of selumetinib (AZD6244/ARRY-142866) in combination with cetuximab (cet) in refractory solid tumors and KRAS mutant colorectal cancer (CRC).
Dustin A. Deming
No relevant relationships to disclose
William R. Schelman
No relevant relationships to disclose
Sam Joseph Lubner
No relevant relationships to disclose
Daniel Mulkerin
No relevant relationships to disclose
Noelle K. LoConte
No relevant relationships to disclose
Suzanne Fioravanti
No relevant relationships to disclose
Tim Greten
No relevant relationships to disclose
Jens C. Eickhoff
No relevant relationships to disclose
Jill Kolesar
No relevant relationships to disclose
Kathryn Compton
No relevant relationships to disclose
Laurence A Doyle
No relevant relationships to disclose
George Wilding
No relevant relationships to disclose
Austin G. Duffy
No relevant relationships to disclose
Glenn Liu
No relevant relationships to disclose